Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0039730 (
thalassemia
)
10,305
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although some cases of the syndrome of hereditary persistence of fetal hemoglobin (HPFH) have been correlated with mutations causing a change in the binding of trans-acting factors to DNA sequences flanking the gamma-globin gene, this mechanism has not been described in beta-thalassemias upstream of the canonical promoter of the beta-globin gene. In this report we describe such a change in binding of a protein that may explain a silent carrier phenotype of beta-
thalassemia
. We have previously demonstrated the binding of a protein (
BP1
) derived from a nuclear extract of human K562 cells to DNA 5' to the human beta-globin gene in a region having a negative regulatory function. The binding of
BP1
in this region can be detected by DNAse I footprinting and by gel mobility shift analysis. We have now compared binding of
BP1
to the normal sequence and a mutated sequence (+ATA/-T at -530 bp from the cap site) from the silent carrier of beta-
thalassemia
. Using mobility shift assays we show that
BP1
binds about nine times more strongly to the mutated sequence than the normal sequence. These results suggest the possibility that the decreased expression of the beta-globin gene exhibited by the carrier may be due, at least in part, to tighter binding of a protein which functions as a negative control element or repressor.
...
PMID:Increased protein binding to a -530 mutation of the human beta-globin gene associated with decreased beta-globin synthesis. 198 81
Beta protein 1
(
BP1
), a human homeotic transcription factor, is expressed during hematopoeisis in the erythroid lineage. To determine the in vivo role of
BP1
in erythropoiesis, we have undertaken two complementary approaches using enforced
BP1
expression in both transgenic mice and embryonic stem (ES) cells. Despite repeated attempts, only one adult transgenic
BP1
founder mouse among 121 mice was obtained. This mouse presumably survived due to transgene mosaicism because the transgene could not be transmitted. This mouse expressed
BP1
and displayed splenomegaly, extramedullary erythropoiesis and severe amyloidosis A in the kidney, a phenotype compatible with
thalassemia
. Consistently, the presence of
BP1
transgene in fetuses was associated with paleness and lethality. In ES cells,
BP1
expression in primary differentiation appeared to antagonize adult beta-globin expression. In secondary differentiation,
BP1
expression reduced significantly beta-globin gene expression in both primitive and definitive erythroid cells, whereas it impaired only the definitive erythroid cell differentiation. These studies showed that
BP1
can negatively modulate adult beta-globin gene expression and definitive erythroid cell differentiation, and suggest that
BP1
could play a role in
thalassemia
.
...
PMID:BP1 is a negative modulator of definitive erythropoiesis. 1700 54
In this report we examine the (AC)n(AT)xTy motif residing -530 bp 5' upstream of the beta-globin gene in Chinese thalassaemic patients. This motif is a putative binding site for a repressor protein, termed
beta protein 1
(
BP1
) (Berg et al., Nucleic Acids Res 1989;17:8833-8852). Variations in the (AC)n(AT)xTy repeats affect the binding affinity of
BP1
, thereby altering the expression of the beta-globin gene. Eight different configurations of this repeat motif are identified in our population of Chinese beta-
thalassaemia
patients. A (AC)3(AT)7T5 motif was identified among these
thalassaemia
patients and its influence in beta-globin gene expression was studied using stable transfection assay in murine erythroleukemia (MEL) cells. Our data demonstrated that the (AC)3(AT)7T5 motif has a moderately strong repressor effect on the expression of the cis-linked beta-globin gene. The high affinity of
BP1
for this motif may result in the suppression of the transcription of the beta-globin gene (Berg et al., Am J Hematol 1991;36:42-47). We postulate that silencer elements in the beta-globin promoter play an important role in modifying the clinical presentation of the disease.
...
PMID:The study of sequence configuration and functional impact of the (AC)n(AT)xTy motif in human beta-globin gene promoter. 1713 28